Merck settles Vioxx Product Liability suits for $4.85 billion
Merck has agreed to pay a fixed amount of $4.85 billion into a settlement fund for qualifying Vioxx claims that enter into the resolution process. This is not a class-action settlement. Claims will be evaluated on an individual basis. According to Richard T. Clark, chairman, president and chief executive officer of Merck, "This is a good and responsible agreement that will allow the Company to concentrate even more fully on its mission of discovering, developing and delivering novel medicines and vaccines."
The conditions in the agreement, is open only to those cases filed or tolled on or before
November 8, 2007.
Click here to read full release from Merck re: Vioxx settlement.
Click here to read Merck Final Vioxx Agreement Signed for outstanding product liability claims.
